Monopar Therapeutics (MNPR) Change in Acquisitions & Divestments (2023 - 2025)

Monopar Therapeutics has disclosed Change in Acquisitions & Divestments across 3 years of filings, most recently posting $16.1 million for Q4 2025.

• Change in Acquisitions & Divestments for Q4 2025 came in at $16.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $23.7 million (up 2304.31% YoY), and the FY2025 annual result was $23.7 million, up 2304.31% from the prior year.
• Change in Acquisitions & Divestments came in at $16.1 million for Q4 2025 at Monopar Therapeutics, up from $3.6 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $16.1 million in Q4 2025 to a low of $985730.0 in Q3 2024.
• The 3-year median for Change in Acquisitions & Divestments is $3.0 million (2023), against an average of $4.2 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 66.66% in 2024 and surged 265.21% in 2025, its largest moves.
• Monopar Therapeutics' Change in Acquisitions & Divestments stood at $3.0 million in 2023, then tumbled by 66.71% to $985730.0 in 2024, then surged by 1533.31% to $16.1 million in 2025.
• The last three Change in Acquisitions & Divestments figures came in at $16.1 million (Q4 2025), $3.6 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.